ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Denali Launches With Big Fund-Raising

by Michael McCoy
May 18, 2015 | APPEARED IN VOLUME 93, ISSUE 20

Denali Therapeutics, a new biotech firm focused on neurodegenerative disease, has launched with an initial investment commitment of $217 million, an amount being called the largest ever for a biotech firm. Denali’s three founders—Ryan Watts, Alexander Schuth, and Marc Tessier-Lavigne—are all former Genentech scientists. Notably, Tessier-Lavigne, now president of Rocke­feller University, led R&D at Genentech during the 2000s. Denali says it plans to discover medicines for Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and other neurodegenerative ailments.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment